Neurocrine Biosciences Inc NBIX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Neurocrine Biosciences to Present Research Advancing Understanding of Prader-Willi Syndrome and Real-World Experience with VYKAT® XR (diazoxide choline) at Foundation for Prader-Willi Research Symposium & Family Conference
-
Neurocrine Biosciences Appoints Eiry W. Roberts, M.D., as Chief Medical Officer
-
Neurocrine Biosciences to Present at Upcoming Investor Conferences in September
-
Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living with Tardive Dyskinesia
-
Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist
-
Neurocrine Biosciences Reports Second-Quarter 2026 Financial Results
-
Neurocrine Biosciences Announces Key Leadership Hiring, Promotions
-
Neurocrine Biosciences Appoints Samir Siddhanti Chief Business Officer
Trading Information
- Previous Close Price
- $140.71
- Day Range
- $140.36–144.56
- 52-Week Range
- $122.14–186.12
- Bid/Ask
- $142.11 / $145.00
- Shares Outstanding
- 101.65M
- Market Cap
- $14.55B
- Volume/Avg
- 2M / 1M
Key Statistics
- Price/Earnings (Normalized)
- 15.92
- Price/Sales
- 4.32
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- 0.46%
Company Profile
Neurocrine Biosciences Inc is a biopharmaceutical firm focused on the research, development, and commercialization of treatments for neurological, psychiatric, endocrine, and immunological disorders. Its portfolio includes therapies for conditions such as tardive dyskinesia, chorea associated with Huntington's disease, classic congenital adrenal hyperplasia due to 21-hydroxylase deficiency, and treatments for endometriosis and uterine fibroids. The company also maintains a pipeline of drug candidates in various stages of clinical and preclinical development across its therapeutic areas, including small molecules, peptides, proteins, antibodies, conjugates, and gene therapies. It derives revenue from the sale of its pharmaceutical products.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Stock Style Box
- Small Core
- Total Number of Employees
- 2,500
- Website
- https://www.neurocrine.com
Competitors
Valuation
|
Metric
|
NBIX
|
TEVA
|
SNY
|
|---|---|---|---|
Price/Earnings (Normalized) | 15.92 | 16.43 | 11.55 |
Price/Book Value | 3.87 | 5.91 | 1.35 |
Price/Sales | 4.32 | 2.64 | 1.73 |
Price/Cash Flow | 13.91 | 15.20 | 7.15 |
Price/Earnings
NBIX
TEVA
SNY
Financial Strength
|
Metric
|
NBIX
|
TEVA
|
SNY
|
|---|---|---|---|
Quick Ratio | 1.46 | 0.46 | 0.49 |
Current Ratio | 1.87 | 0.88 | 0.99 |
Interest Coverage | — | 1.79 | 8.05 |
Quick Ratio
NBIX
TEVA
SNY
Profitability
|
Metric
|
NBIX
|
TEVA
|
SNY
|
|---|---|---|---|
Return on Assets (Normalized) | 19.82% | 6.68% | 7.96% |
Return on Equity (Normalized) | 28.47% | 35.32% | 14.96% |
Return on Invested Capital (Normalized) | 25.19% | 14.43% | 11.28% |
Return on Assets
NBIX
TEVA
SNY
Drug Manufacturers - Specialty & Generic Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Merck KGaA ADR
MKKGY
| LOCK|sC>@?>! | LOCK|@g<#D | $66B | |||
| Teva Pharmaceutical Industries Ltd
TEVA
| LOCK|ny!t?!BL | LOCK|<>L%v | $46B | |||
| Haleon PLC ADR
HLN
| LOCK|$&rd$N? | LOCK|$!k | $38B | |||
| Zoetis Inc Class A
ZTS
| LOCK|>q?#$t!@ | LOCK|#?$ | $29B | |||
| Viatris Inc
VTRS
| LOCK|F^y!ry@ | LOCK|@v | $20B | |||
| Elanco Animal Health Inc
ELAN
| LOCK|%D | LOCK|vFf | $11B | |||
| Dr Reddy's Laboratories Ltd ADR
RDY
| LOCK|Qb^NXy | LOCK|Pr | $10B | |||
| Hims & Hers Health Inc Ordinary Shares - Class A
HIMS
| LOCK|W<zBc@Y | LOCK|p^ | $7B | |||
| Prestige Consumer Healthcare Inc
PBH
| LOCK|WtL<j< | LOCK|ZMQC | $2B | |||
| Perrigo Co PLC
PRGO
| LOCK|@WD&CC | LOCK|sLc | $2B |
United States